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SUMMARY
This article presents a predictive molecular signature that
marks the early onset of ﬁbrosis in a translational nonal-
coholic steatohepatitis mouse model. Overlap of genes and
processes with human nonalcoholic steatohepatitis and a list
of top candidate biomarkers for early ﬁbrosis are described.
BACKGROUND & AIMS: The incidence of nonalcoholic stea-
tohepatitis (NASH) is increasing. The pathophysiological
mechanisms of NASH and the sequence of events leading to
hepatic ﬁbrosis are incompletely understood. The aim of this
study was to gain insight into the dynamics of key molecular
processes involved in NASH and to rank early markers for
hepatic ﬁbrosis.
METHODS: A time-course study in low-density
lipoprotein–receptor knockout. Leiden mice on a high-fat diet
was performed to identify the temporal dynamics of key
processes contributing to NASH and ﬁbrosis. An integrative
systems biology approach was used to elucidate candidate
markers linked to the active ﬁbrosis process by combining
transcriptomics, dynamic proteomics, and histopathology. The
translational value of these ﬁndings were conﬁrmed using
human NASH data sets.
RESULTS: High-fat-diet feeding resulted in obesity, hyperlip-
idemia, insulin resistance, and NASH with ﬁbrosis in a
time-dependent manner. Temporal dynamics of key molecular
processes involved in the development of NASH were identi-
ﬁed, including lipid metabolism, inﬂammation, oxidative stress,
and ﬁbrosis. A data-integrative approach enabled identiﬁcation
of the active ﬁbrotic process preceding histopathologic detec-
tion using a novel molecular ﬁbrosis signature. Human studies
were used to identify overlap of genes and processes and to
perform a network biology-based prioritization to rank top
candidate markers representing the early manifestation of
ﬁbrosis.
CONCLUSIONS: An early predictive molecular signature was
identiﬁed that marked the active proﬁbrotic process before
histopathologic ﬁbrosis becomes manifest. Early detection
of the onset of NASH and ﬁbrosis enables identiﬁcation of
novel blood-based biomarkers to stratify patients at risk,
development of new therapeutics, and help shorten (pre)clinical
experimental time frames. (Cell Mol Gastroenterol Hepatol
2018;5:83–98; https://doi.org/10.1016/j.jcmgh.2017.10.001)
Keywords: Systems Biology; Metabolic Syndrome; Liver Disease;
Diagnosis.
See editorial on page 65.
Nonalcoholic fatty liver disease (NAFLD) has becomethe most common chronic liver disease in devel-
oped countries.1 This increasing prevalence is associated
closely with the incidence of obesity, insulin resistance, and
dyslipidemia, all of which are risk factors for NAFLD.2–5
NAFLD is associated with 26% higher overall health care
costs, mainly from associated cardiometabolic diseases,6
and is projected to become the primary indication for
liver transplantation within the next several years.7 NAFLD
encompasses a spectrum of liver diseases ranging from the
relatively benign hepatic steatosis to nonalcoholic steato-
hepatitis (NASH), the progressive form of NAFLD.
NASH is characterized by the presence of hepatocellular
damage and inﬂammation,8 which in concert can drive the
development of ﬁbrosis.9 Recently, liver ﬁbrosis was recog-
nized to be strongly associated with long-term overall
mortality, independently of other histologic features of
NAFLD or NASH.10,11 There is currently nomethod to identify
which patient will progress from NAFLD and/or NASH to
ﬁbrosis. In addition, NASH and liver ﬁbrosis are clinically
silent, with hardly any symptoms,whichmeans that detection
often does not occur until the advanced stages of disease.
The molecular and cellular mechanisms involved in the
pathogenesis of NAFLD and NASH have not been elucidated
completely yet, but it is clear that disease progression is the
result of complex and dynamic interactions between many
processes, such as lipid metabolism, inﬂammation, oxidative
stress, and ﬁbrosis. However, the current body of knowledge
relies mostly on results from studies that investigate these
processes ata single timepoint (generally endpointpathology)
rather than investigating their interplay and dynamics over
time. Information on the temporal dynamics and interaction
between variousmolecular and pathologic processes has been
shown to provide insight into early diseasemanifestations and
allow detection of the onset of progressive disease.12
Animal models of NAFLD and NASH can be used for
time-resolved studies and are suitable to provide crucial
information on the processes that contribute to disease
development. In the current study, we investigated the
development of NASH in a time-resolved manner in high-fat-
diet–fed low-density lipoprotein-receptor knockout
(LDLr-/-.Leiden) mice, which develop NASH and hepatic
ﬁbrosis in the context of obesity, dyslipidemia, and insulin
resistance, as is typical for NASH patients.13 Dynamic pro-
teomic analyses that involve deuterated water labeling and
tandem mass spectrometry were used to measure the
formation of new collagens representing the active ﬁbrosis
process.14–16 RNA sequencing was used to generate a genetic
time-resolved proﬁle of processes involved in the develop-
ment of NASH. This allowed identiﬁcation of the dynamics
of key molecular processes involved in the development of
NASH and ﬁbrosis. An integrative systems biology approach
was used to investigate the molecular processes involved in
the active ﬁbrosis process by combining transcriptomics,
dynamic proteomics, and histopathology. To gain insight into
the translational value of these ﬁndings, the LDLr-/-.Leiden
NASH mouse was compared with NASH patients on the
molecular level. In addition, network biology-based ranking
was performed using databases containing data from human
cohort studies to identify candidate markers that represent
the early manifestation of ﬁbrosis.
Materials and Methods
Animals and Housing
Animal experiments were approved by an independent
Animal Care and Use Committee and were in compliance
with European Community speciﬁcations for the use of
laboratory animals.
Time-Course Study
Twelve-week-old male LDL-receptor knockout mice
were obtained from the breeding facility of TNO Metabolic
Health Research (Leiden, The Netherlands). Animals
received either standard rodent chow (Sniff-R/M-V1530
with 33 kcal% protein, 58 kcal% carbohydrate, and 9 kcal%
fat; Uden, The Netherlands) (N ¼ 45) or a high-fat diet
(HFD) (D12451; Research Diets, Inc, New Brunswick,
NJ; with 20 kcal% protein, 35 kcal% carbohydrate, and 45
kcal% lard fat) (N ¼ 75) for a total of 30 weeks. Mice were
group-housed in the speciﬁed pathogen free animal facility
of TNO Metabolic Health Research, in a temperature-
controlled room on a 12-hour light/dark cycle with ad
libitum access to food and water. All interventions were
performed during the light cycle. Groups were sacriﬁced
after 6, 12, 18, 24, and 30 weeks on the diets. Blood samples
were collected via the tail vein for EDTA plasma isolation
after a 5-hour fast at 6-week intervals. A subset of mice
(chow, n ¼ 6; HFD, n ¼ 15) was sacriﬁced every 6 weeks.
This subset was matched to the remaining mice for body
weight and the biochemical parameters of plasma choles-
terol, triglycerides, blood glucose, and insulin. One group of
mice (n ¼ 15) was sacriﬁced before the start of the diets to
*Authors share co-ﬁrst authorship.
Abbreviations used in this paper: ALT, alanine aminotransferase; AST,
aspartate aminotransferase; DEG, differentially expressed genes;
ECM, extracellular matrix; HFD, high-fat diet; IPA, Ingenuity Pathway
Analysis; LDLr-/-, low-density lipoprotein receptor knock out; NAFLD,
nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis;
THBS1, thrombospontin-1.
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deﬁne the starting condition (time [t] ¼ 0). In the 18-week
and 24-week groups, 1 animal died before sacriﬁcing, which
was not included in the analyses (resulting in HFD, n ¼ 14
for these 2 time points). One week before sacriﬁce, all mice
received an intraperitoneal injection with deuterated water
(35 mL/g body weight) followed by 8% deuterated water in
the drinking water until sacriﬁce to allow for dynamic
proteomics analyses. Animals were terminated by CO2
asphyxiation, and a terminal blood sample (for EDTA
plasma) was collected by cardiac puncture. Liver and adi-
pose tissue depots were isolated. Tissues were partly ﬁxed
in formalin and parafﬁn-embedded for histologic analysis
and partly snap frozen in liquid nitrogen and stored at -80C
for RNA isolation and dynamic protein proﬁling.
Biochemical Analysis of Circulating Factors
Total plasma cholesterol and triglycerides were measured
with enzymatic assays (Roche Diagnostics, Almere, The
Netherlands). Blood glucose level was measured immediately
during blood sampling using a hand-held glucose analyzer
(FreeStyle Lite, Abbot Laboratories, Hoofddorp, the
Netherlands). Plasma insulin levelwasdeterminedbyenzyme-
linked immunosorbent assay (ultrasensitive mouse insulin
enzyme-linked immunosorbent assay; Mercodia, Uppsala,
Sweden). Plasma alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST) levels were measured using a
spectrophotometric activity assay (Reﬂotron-Plus; Roche Di-
agnostics). HOmeostatic Model Assessment for Insulin Resis-
tance was used to evaluate insulin resistance (fasting plasma
insulin [mg/L] fasting plasma glucose [mmol/L]/22.5).17
Intrahepatic Lipid Analysis
Liver lipids were analyzed by high-performance thin-
layer chromatography as described previously.18 Brieﬂy,
lipids were extracted from liver homogenates using meth-
anol and chloroform following the Bligh and Dyer19 method,
after which they were separated by high-performance thin-
layer chromatography on silica gel plates as described
previously.20 Lipid spots were stained with color reagent,
and triglycerides, cholesteryl esters, and free cholesterol
were quantiﬁed using TINA software version 2.09 (Raytest,
Straubenhardt, Germany).
Histologic Analysis
For histologic analysis of liver, 3-mm–thick cross-sections
of the median lobe were stained with H&E. NAFLD was
scored blindly by a board-certiﬁed liver pathologist using a
general scoring system for rodent models, which is based on
the human NASH Activity Score grading criteria.21 Brieﬂy, 2
cross-sections per mouse were examined and the level of
microvesicular and macrovesicular steatosis was expressed
as a percentage of the cross-sectional area. Hepatocellular
hypertrophy (hepatocyte size > 1.5 normal diameter) was
determined and expressed as the percentage of the total liver
slide area. Hepatic inﬂammationwas assessed by counting the
number of inﬂammatory foci per ﬁeld at a magniﬁcation of
100 in 5 nonoverlapping ﬁelds per specimen, expressed as
the average number of foci per mm2 ﬁeld. Fibrosis was
assessed histochemically by Picro-Sirius Red staining
(Chroma; WALDECK-GmbH, Munster, Germany). Collagen
content was quantiﬁed using ImageJ Software (National In-
stitutes of Health, Bethesda, MD) by assessment of the area of
liver tissue that was stained positively (expressed as the
percentage of total tissue area). In addition, the development
of ﬁbrosis was assessed by a liver pathologist to quantify the
percentage of perisinusoidal ﬁbrosis (expressed as the per-
centage of perisinusoidal ﬁbrosis relative to the total peri-
sinusoidal area).
Mouse Hepatic Gene Expression Analysis
Total RNA was extracted from the liver at all time points
(n ¼ 6 for chow group/time point and n ¼ 12 for HFD
group/time point), with Ambion RNAqueous total RNA
isolation kit (Thermo Fisher Scientiﬁc, Inc, Waltman, MA).
The RNA concentration was determined spectrophotomet-
rically using Nanodrop 1000 (Isogen Life Science, De Meern,
The Netherlands), and RNA quality was assessed using the
2100 Bioanalyzer (Agilent Technologies, Amstelveen, The
Netherlands). Strand-speciﬁc messenger RNA sequencing
libraries for the Illumina (San Diego, CA) platform were
generated and sequenced at BaseClear BV (Leiden, The
Netherlands). The libraries were multiplexed, clustered, and
sequenced on an Illumina HiSeq 2500 with a single-read 50-
cycle sequencing protocol, 15 million reads per sample, and
indexing. Differentially expressed genes (DEGs) were
determined at weeks 6, 12, 18, and 24 using the DEseq-
method with statistical cut-off false discovery rate of less
than 0.001.22 DEGs were used as an input for pathway
analysis through Ingenuity Pathway Analysis (IPA) suite
(www.ingenuity.com, accessed 2016).
Dynamic Proteomics
A dynamic proteomics platform described previously23,24
was applied to quantify the fractional synthesis rates of a
large numbers of proteins via stable isotope labeling and
liquid chromatography–mass spectrometry–based mass
isotopomer analysis. Brieﬂy, mice were labeled with
deuterated water for 7 days, frozen liver tissue (chow, n¼ 3;
HFD, n ¼ 4) was subjected to sequential protein extraction
to fractionate cellular, guanidine-soluble extracellular matrix
(ECM) proteins and residual insoluble ECM proteins, and
protein fractional synthesis rates (fraction of each protein
that had been newly synthesized during the 7-day labeling
period) were calculated using mass isotopomer analyses as
described previously.25
Translational Aspects of LDLr-/-.Leiden NASH
Mouse Model
To gain insight into the translational value of the
LDLr-/-.Leiden NASH mouse model, a comparison was made
at the molecular level between the LDLr-/-.Leiden mouse and
data from NASH patients. The human gene expression data
set (GSE48452) was downloaded from Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo) including 12
control liver samples (group C), 16 healthy obese samples
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(group H), 9 steatosis samples (group S), and 17 NASH
samples (group N). This data set was derived from a study
performed by the laboratory of Dr J. Hampe (Kiel,
Germany). From this data set, samples were used that
were obtained before the patients underwent a gastric
bypass surgery.26 Gene expression levels were measured
using the Affymetrix Human Gene 1.1 ST array (transcript
version) (Affymetrix, Inc, Santa Clara, CA). The probe-level,
background-subtracted, expression values were used as
input for the lumi package27 of the R/Bioconductor
(http://www.bioconductor.org; http://www.r-project.org)
to perform quality control and quantile normalization.
Differentially expressed probes were identiﬁed using the
limma package of R/Bioconductor,28,29 and calculated
values of P < .01 were used as the threshold for
signiﬁcance. These differentially expressed probes were
used as input for pathway analysis through IPA suite
(www.ingenuity.com, accessed 2017).
Feature Selection for Molecular
Fibrosis Signature
Identiﬁcation and ranking of features (genes and pro-
teins) for the molecular ﬁbrosis signature was obtained by
calculating a rank/composite score based on 3 approaches:
correlation analyses (Pearson and Spearman) to link
differentially expressed genes to newly formed proteins;
weighted association of genes and proteins to key disease
processes (direct and indirect biological link); and the
presence of genes/proteins in a biomarker database
Figure 1. Effect of HFD
and chow on (A) body
weight, and plasma
levels of (B) cholesterol,
(C) triglycerides, (D)
insulin, and (E) glucose,
and (F) HOMA index.
Black solid squares indi-
cate HFD; open circles
indicate chow diet.
*P < .05, **P < .01,
***P < .001 vs chow.
HOMA-IR, HOmeostatic
Model Assessment for In-
sulin Resistance.
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(Integrity Biomarker Module; Thomson Reuters, London)
for NASH and hepatic ﬁbrosis, or other ﬁbrotic diseases.
The approaches in more detail were as follows: the
Pearson correlation coefﬁcient was calculated for all
normalized gene counts (expressed as Reads Per Kilobase
per Million mapped reads30) per subject and fractional
synthesis rates from the dynamic proteome analysis.25
Because the Pearson correlation method is prone to
induce a bias in feature selection because of the presence
of potential outliers, Spearman rank correlation also was
performed on the same data set. Features were selected for
the ﬁbrosis signature when both the Pearson and
Spearman correlation coefﬁcient were greater than 0.9 (P
< .01). The feature list of the ﬁbrosis signature resulted in
232 genes and 8 proteins that were used as the seed list for
the association to key disease processes (direct biological
link). The Path Explorer tool (IPA; Qiagen, Redwood City,
CA) was used to calculate the shortest path between 232
signature genes and deﬁned 4 key processes. This algo-
rithm connects predeﬁned molecules such as the ﬁbrosis
signature to other molecules or processes using the
curated knowledge from Ingenuity Knowledge Base
(Qiagen). Because not all genes could be linked directly to
these processes, the biological context of the remaining
genes and proteins was determined by building an induced
modules networks using databases within Con-
sensusPathDB (http://cpdb.molgen.mpg.de/), indicated as
the indirect biological link. The interactions from Con-
sensusPathDB were visualized in Gephi using ForceAtlas2,
a continuous graph layout algorithm31 for network visu-
alization. Final prioritization was obtained by identiﬁcation
of which of the 232 genes and 8 proteins were documented
in the Integrity biomarker module (accessed March 2017)
and used as a biomarker in human studies (clinical trials
and observational studies) related to NASH, hepatic
ﬁbrosis, or other ﬁbrotic diseases.
Statistical Analysis
In vivo data are presented as means ± SD. The signiﬁ-
cance of differences between chow and HFD animals in
continuous variables were tested using a 2-way analysis of
variance with the Bonferroni post hoc test. Statistical
Figure 2. Effect of HFD
and chow diet on liver
characteristics such as
liver damage enzymes (A)
ALT and (B) AST, (C) liver
weight, and (D) liver lipids
free cholesterol, (E) tri-
glycerides, and (F) cho-
lesteryl esters. Black solid
squares indicate HFD;
open circles indicate chow
diet. **P < .01, ***P < .001
vs chow.
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differences between HFD and chow-fed animals were tested
using the Student t test. Differences with a P value less than
.05 were considered signiﬁcantly different.
Results
HFD Feeding Induces Obesity,
Hypercholesterolemia, Hypertriglyceridemia, and
Insulin Resistance
At the start of the experiment, mice from both groups
had an equal average body weight of 28.2 ± 2.4 g (chow
group) and 28.3 ± 2.4 g (HFD group). Body weight increased
in HFD-fed mice relative to chow-fed mice, and was statis-
tically signiﬁcant after 6 weeks of HFD treatment (HFD, 40.4
± 3.2 vs chow, 31.3 ± 3.1 g; P < .001). This difference in
body weight was sustained until the end of the study at
week 30 (Figure 1A). This body weight increase was re-
ﬂected by increased weights of various white adipose tissue
depots (data not shown). HFD feeding resulted in an obese
phenotype with obesity-associated hypercholesterolemia,
hypertriglyceridemia, and hyperinsulinemia (Figure 1B–D).
All parameters showed a strong increase from week 6 until
week 18 and remained at this increased level until the end
of the study. Although blood glucose levels were not
increased signiﬁcantly at all time points (Figure 1E), the
HOMA index indicated that HFD-fed mice became insulin
resistant from week 6 until week 24 (Figure 1F), indicating
appropriate b-cell compensation.
HFD Feeding Induces NAFLD, Which Progresses
to NASH Over Time
In parallel with the development of an obese phenotype,
plasma levels of liver damage markers ALT and AST
increased signiﬁcantly upon HFD feeding. Plasma levels of
ALT and AST were increased rapidly and signiﬁcantly from
6 weeks onward in HFD vs chow mice (Figure 2A and B).
Liver weight in HFD-fed animals was increased signiﬁcantly
relative to chow-fed animals after week 18 (Figure 2C).
Biochemical analysis of intrahepatic lipids showed that free
cholesterol in the liver was increased signiﬁcantly at weeks
18 and 24 in HFD-fed animals (Figure 2D). Liver triglyceride
levels reached a maximum at week 18 and remained at this
level up until week 30 (Figure 2E). Cholesteryl esters
already were increased signiﬁcantly at week 6 and
remained increased signiﬁcantly at all later time points
(Figure 2F).
Histopathologic analysis of hepatic steatosis (both
microvesicular and macrovesicular), hepatocellular hyper-
trophy, hepatic inﬂammation, and hepatic ﬁbrosis showed
the development of NASH with ﬁbrosis on prolonged HFD
feeding (Figure 3). In HFD-fed animals both macrovesicular
Figure 3. Histologic ﬁgures of H&E staining (top panels) and Picro-Sirius Red (PSR) staining (bottom panels) of relevant
time points (t) shows the development of NASH and ﬁbrosis in the HFD-fed LDLr-/-.Leiden mice.
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and microvesicular steatosis were pronounced at week 6
and increased until week 18 (Figure 4A and B). Mild liver
cell hypertrophy was detectable at week 6, and strongly
increased until week 18, after which no further increase was
observed (Figure 4C). In contrast, the number of inﬂam-
matory aggregates in the liver in HFD mice was comparable
at weeks 6 and 12, and showed a strong but variable in-
crease starting at week 18 (Figure 4D). Histopathologic liver
ﬁbrosis was not present at weeks 6 and 12, but became
detectable at week 18 and showed a gradual increase up
until week 30 (Figure 4E).
Transcriptome Analysis Showed Dynamics of
Key Processes Involved in NASH and Fibrosis
To unravel the molecular processes affected during the
development of NASH and ﬁbrosis and to provide insight
into their time-resolved patterns of regulation during dis-
ease progression, next-generation sequencing of hepatic
gene expression was performed. HFD feeding substantially
increased the number of DEGs compared with chow feeding,
ultimately leading to 2888 and 2753 DEGs (false discovery
rate < 0.001) at weeks 18 and 24, respectively (Figure 5A).
Analysis of the degree of overlap between the different time
points shows that the majority of genes expressed at weeks
18 and 24 are shared. In addition, a large proportion of the
genes that are differentially expressed at week 12 remain
differentially regulated at weeks 18 and 24, as shown in the
Venn diagram (Figure 5B). Gene set enrichment analysis
indicated a clear modulation of pathways related to NASH
and hepatic ﬁbrosis at week 24 after HFD treatment, as
exempliﬁed by expression changes of genes in lipid meta-
bolism pathways and a strong activation of genes in the
hepatic ﬁbrosis/hepatic stellate cell activation and integrin
signaling pathways. In addition, among the top canonical
pathways, 13 inﬂammation-related pathways and oxidative
stress response pathways were activated by the HFD
treatment compared with chow (Figure 5C). Integration of
Figure 4. Pathologic fea-
tures of NASH after HFD
and chow diet deter-
mined by the level of (A)
microvesicular steatosis,
(B) macrovesicular stea-
tosis vacuolation, (C)
hepatocellular hypertro-
phy, (D) hepatic inﬂam-
mation, and the level of
(E) perisinusoidal ﬁbrosis.
Black bars indicate HFD,
white bars indicate chow
diet. ***P < .001 vs chow.
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expression data from all time points clearly showed a time-
resolved response of the main categories of processes that
play a role in the development of NASH and hepatic ﬁbrosis,
namely lipid metabolism, inﬂammation, oxidative stress,
and ﬁbrosis (Figure 6). The process of lipid metabolism is
the ﬁrst to be activated (from week 6 onward), while the
inﬂammatory, oxidative stress, and ﬁbrotic response were
activated from week 12 onward. These data show early
response genes and processes from all main categories that
already were expressed differentially in week 12.
Dynamic Proteomic Analyses Uncovers Early
Synthesis of Extracellular Matrix Proteins
Next, we investigated whether these pronounced effects
of HFD feeding on gene expression also were reﬂected on
the protein level by measuring protein turnover rates, using
deuterated water-labeled. This dynamic protein analysis
was performed, using the guanidine-soluble and guanidine-
insoluble proteins from liver, to provide insight into the
proteins that were synthesized during the last week before
sacriﬁce (expressed as a fractional synthesis value; ie, the
fraction of each protein that was newly synthesized during
the 7-day labeling period). The guanidine-soluble fraction
contained many extracellular matrix proteins, of which the
synthesis rate was increased signiﬁcantly at an early time
point (week 6 or 12) and that remained high during the
progression of liver disease (week 24); these included
biglycan, collagen1a1, collagen1a2, collagen6a1, fumar-
ylacetoacetase, keratin type I cytoskeletal 18, keratin type II
cytoskeletal 8, and nidogen-1. The guanidine-insoluble
fraction also contained several extracellular matrix pro-
teins, of which the synthesis rate was signiﬁcantly different
from chow-fed mice at an early stage of disease and
Figure 5. (A) Effect of HFD
on the number of differ-
entially expressed genes
as measured by RNA
sequencing technology.
Visualization of overlapping
genes per time point rep-
resented in a (B) Venn dia-
gram and (C) enrichment
analysis of the top 25
enriched canonical path-
ways, values are expressed
as -log(P value). Red stars
indicate pathways related
to lipid metabolism, green
stars are related to inﬂam-
matory processes, blue
stars are related to oxida-
tive stress, and purple stars
are related to extracellular
matrix processes.
90 van Koppen et al Cellular and Molecular Gastroenterology and Hepatology Vol. 5, No. 1
remained different during the progression of liver disease,
including collagen1a1, collagen3a1, collagen4a1,
collagen4a2, collagen6a1, collagen6a2, laminin subunit g1,
and several tubulins (data not shown). To visualize the
protein synthesis rate, a heatmap was generated based on
fold-change differences (Figure 7). The most predominant
difference was seen in a cluster of proteins involved in ECM
deposition and ﬁbrosis, which already was abundant after
12 weeks of HFD treatment (Figure 7, between the dashed
lines). These data show increased extracellular matrix syn-
thesis already after 12 weeks of HFD feeding by dynamic
protein proﬁling analysis, a time point at which histopath-
ologic ﬁbrosis was not detectable yet.
LDLr-/-.Leiden NASH Mouse Model Shares
Genes and Processes With NASH Patients
To determine the translational value of the molecular
changes in the LDLr-/-.Leiden NASH mouse model a com-
parison analysis was performed using data from human
NASH patients (GSE48452). A total of 123 genes (mapped
cross-species) were selected that were differentially
expressed between NASH patients and healthy controls as
previously determined by Teufel et al.32 From these 123
genes, 71 genes were identiﬁed to be expressed in a time-
dependent manner in HFD-fed LDLr-/-.Leiden mice, with
the majority of genes being regulated in the same direction
as in human beings (Figure 8A). Because analysis on
individual gene level may overlook common disease mech-
anisms, we compared gene set enrichments between
LDLr-/-.Leiden mice at week 24 with NASH patients. Inter-
estingly, the previously identiﬁed key processes in mice
(Figures 5C and 6) involved in the development of NASH
also were enriched in the top 18 pathways in human NASH
patients (Figure 8B). This indicates that the LDLr-/-.Leiden
mouse model can be used to study key processes related to
NASH and generate data that reﬂect the human situation.
Feature Selection to Generate an Early Fibrosis
Signature and Rank Candidate Biomarkers
An increased expression of ﬁbrosis-related genes and
molecular processes as well as synthesis of new matrix
proteins was detected already at week 12 and preceded
histopathologic detection. Next, a data integrative genomics-
proteomics approach was applied to select and prioritize the
speciﬁc molecular features that enable early detection of
hepatic ﬁbrosis. First, the HFD-induced differentially
expressed 2753 genes from week 24, a time point at which
hepatic ﬁbrosis was abundant, were compared with the
differentially expressed genes at week 12. This resulted in a
total of 568 differentially expressed genes that were up-
regulated at weeks 24 and 12. Next, a selection of 33
newly formed proteins were identiﬁed that were statisti-
cally different compared with chow animals at both weeks
24 and 12 (P < .05). Correlation analysis of these 568 DEGs
with 33 statistically different proteins at week 24 resulted
in a list of 232 genes that were strongly correlated with 8
proteins (R2 > 0.9; P < .01) (Supplementary Table 1). This
set of genes and proteins was designated as the molecular
ﬁbrosis signature, of which the biological relevance was
investigated further. By using the Path Explorer tool
including the Shortest Path algorithm, 88 DEGs were iden-
tiﬁed to be linked directly to the 4 major processes of lipid
metabolism, inﬂammatory response, oxidative stress, and
ﬁbrosis (Figure 9A). To determine relations between the
remaining genes and the dynamic proteins, an induced-
modules networks (Figure 9B) was generated connecting
144 genes and 5 proteins. This indicated clusters of genes/
proteins, of which one was highly related to the ECM and
the other indicated genes under control of TAF1, a tran-
scription factor that regulates cell proliferation by affecting
the transforming growth factor-b signaling pathway. Next,
the relevance of these genes and proteins were calculated
(composite score) based on their connection directly or
indirectly to one or more key biological processes, whether
they were documented in the literature as a biomarker for
NASH, hepatic ﬁbrosis, or another ﬁbrotic disease, and
based on the fold-change in HFD condition compared with
control chow at week 12 (Supplementary Table 2). An
overview of the top 20 most relevant genes and proteins
and the calculated composite scores are shown in Table 1.
To illustrate the relevance of these genes and proteins the
correlation between gene expression and histologic grade of
ﬁbrosis as measured by Picro-Sirius Red staining was
determined. This further strengthened the relationship be-
tween signature gene expression and hepatic ﬁbrosis.
Discussion
The development of NASH and hepatic ﬁbrosis is a long-
term progressive process. The sequence of molecular events
that contribute to the development of NASH and ﬁbrosis is
largely unknown. This is partly due to the late diagnosis of
NASH and ﬁbrosis because their clinical symptoms do not
become manifest until an advanced stage of disease.
Therefore, it is difﬁcult to study the early processes involved
in disease development in human beings. Animal models of
Figure 6. Graphic visualization of temporal dynamics of
key processes involved in the development of NASH and
ﬁbrosis as determined by time-resolved enrichment
analysis of the top canonical pathways. Red line, lipid
metabolism; green line, inﬂammatory processes; blue line,
oxidative stress; purple line, extracellular matrix processes.
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Figure 7. Heatmap visual-
ization of the effect of
HFD on signiﬁcant liver
proteins synthesized the
week before sacriﬁce as
measured by dynamic
protein proﬁling using
deuterated water labeling
technique. The black box
with dashed lines indicates
the set of ECM proteins.
Green indicates down-
regulation, red indicates
up-regulation.
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NASH allow time-resolved analysis of events that shows
crucial information on early processes contributing to dis-
ease development. For such analysis the translational
aspects of the mouse model used are a prerequisite.
To study mechanisms of disease development, a wide
variety of animal models for NASH and ﬁbrosis are available,
which all have their speciﬁc advantages and disadvan-
tages.33,34 None of these resembles the complete spectrum
of molecular processes involved in the development of
NASH and ﬁbrosis in human beings.32 However, to study
NASH and ﬁbrosis in a more physiological setting,
HFD-induced models better represent human disease
development, although the degree of liver injury and ﬁbrosis
is less severe than in chemically induced (eg, carbon tetra-
chloride) ﬁbrosis.35
HFD-fed LDLr-/-.Leiden mice develop characteristics
of the metabolic syndrome indicated by obesity, hyper-
cholesterolemia, hypertriglyceridemia, and insulin resis-
tance. As a consequence of HFD feeding, liver damage
occurred, as indicated by increased levels of ALT and AST
Figure 8. Heatmap visualization of individual genes compared with their controls. Human NASH indicates the gene
response of human NASH patients compared with health control subjects. LDLr-/-.Leiden mice indicates the gene response of
HFD-fed mice compared with chow at the corresponding time point. (A) Green indicates down-regulation, red indicates
up-regulation. (B) Visualization of the enrichment analysis of the top 25 enriched canonical pathways, values are expressed as
-log(P value). Red stars indicate pathways related to lipid metabolism, green stars are related to inﬂammatory processes, and
purple stars are related to extracellular matrix processes.
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relative to chow-fed controls. Furthermore, liver damage
was conﬁrmed by histopathologic analysis, which showed
a gradual increase of steatosis, cellular hypertrophy, and
inﬂammation over time. More importantly, LDLr-/-.Leiden
mice also developed hepatic perisinusoidal ﬁbrosis. These
results show that the LDLr-/-.Leiden mouse model is a
suitable model for NASH with associated hepatic ﬁbrosis
in the context of obesity, dyslipidemia, and insulin resis-
tance,20 as is typical for NASH patients.1 By using a
systems biology approach we have provided a time-
dependent sequence of key molecular processes
involved in the development of NASH and ﬁbrosis. This
Figure 9. (A) Network visualization of the direct link between features of the molecular signature associated with key
processes, lipid metabolism, inﬂammation, oxidative stress, and ﬁbrosis, and (B) the indirect link via induced-modules
network. Yellow nodes indicate key processes, red nodes indicate genes and proteins from the signature, and green nodes
indicate nodes from the induced modules network.
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approach allowed us to unravel the mechanisms of dis-
ease development, enabled early identiﬁcation of disease
processes leading to hepatic ﬁbrosis, and can guide the
development of tools for the discovery of blood-based
biomarkers for ﬁbrosis.
To determine the translational value of our ﬁndings we
compared mouse-derived data with human data using a
publicly available NASH patient data set (Gene Expression
Omnibus dataset: GSE48452). In a previous study, Teufel
et al32 identiﬁed a panel of 123 genes differentially
expressed in NASH patients compared with healthy controls.
Although Teufel et al32 reported only few (range, 1–18)
overlapping genes between several NASH mouse models
and NASH patients, we showed in the current study that the
majority (71) of these 123 genes also could be detected in
our LDLr-/-.Leiden mouse model. Because an analysis of the
individual gene level may depreciate common disease
mechanisms, we compared gene set enrichments between
HFD-fed LDLr-/-.Leiden mice at week 24 with NASH pa-
tients. These data illustrate the overlap between NASH pa-
tients and HFD-fed LDLr-/-.Leiden mice on NASH-related
processes. Results obtained in this LDLr-/-.Leiden NASH
mouse model on these key processes therefore might have
clinical relevance.
We identiﬁed the temporal dynamics of key molecular
processes involved in the development of NASH, namely
lipid metabolism, inﬂammatory response, oxidative stress,
and ﬁbrosis. This was supported by time-resolved
histopathologic observations showing similarities to human
disease development. Furthermore, these data support the
multiple-hit hypothesis, which considers multiple processes
acting together to induce NASH and ﬁbrosis.36 This includes
triglyceride accumulation and associated lipotoxicity fol-
lowed by, at least in part, a proinﬂammatory reaction and
oxidative stress response, and a proﬁbrotic process leading
to the synthesis of new extracellular matrix and deposition
of collagens. The clinical symptoms of this proﬁbrotic pro-
cess do not become manifest until an advanced stage of
disease, at which time disease development is difﬁcult to
treat. Therefore, it is important to identify proﬁbrotic pro-
cesses at an early time point at which pathologic ﬁbrosis is
not present yet.
Data integrative approaches were used to correlate a
subset of differentially expressed genes to the active for-
mation of newly formed collagen, which was synthesized in
the week before animals were sacriﬁced. This resulted in the
identiﬁcation of a molecular ﬁbrosis signature associated
with key disease processes, which can be detected at the
molecular level before histopathologic ﬁbrosis becomes
manifest. This shows a molecular readout that can be used as
a molecular diagnostic tool for the detection of early hepatic
ﬁbrosis. In a clinical setting, the use of molecular diagnostics
already is used to perform prognostic risk assessments for
several diseases including hepatocellular carcinoma37,38 and
breast cancer.39 To our knowledge, molecular diagnostics
based on a combination of transcriptomics and dynamic
Table 1.Overview of the Top 20 Most Relevant Genes and Proteins Based on Their Calculated Composite Scores and
Correlations With Histopathologic Fibrosis Score
Gene name
Expression
change, logFC
Documented
biomarker
for NASH
Documented
biomarker for
hepatic ﬁbrosis
Composite
score
Correlation
Sirius Red Ensemble gene ID
SERPINE1 3.0 Y Y 16.1 0.858 ENSMUSG00000037411
CCL2 2.0 Y Y 11.2 0.853 ENSMUSG00000035385
COL1A1 2.4 Y Y 10.5 0.862 ENSMUSG00000001506
THBS1 2.1 Y Y 9.3 0.961 ENSMUSG00000040152
CXCL10 2.1 Y Y 9.3 0.788 ENSMUSG00000034855
CCR2 1.7 Y Y 9.3 0.975 ENSMUSG00000049103
CD14 1.9 Y Y 8.6 0.851 ENSMUSG00000051439
IL1RN 2.5 Y N 8.4 0.749 ENSMUSG00000026981
TNC 1.4 Y N 6.5 0.890 ENSMUSG00000028364
SMPD3 2.7 N N 6.5 0.880 ENSMUSG00000031906
PLAU 1.3 N Y 6.3 0.882 ENSMUSG00000021822
COL3A1 1.8 Y Y 6.3 0.927 ENSMUSG00000026043
APOA4 2.6 Y N 6.3 0.808 ENSMUSG00000032080
MMP12 5.2 N N 6.2 0.842 ENSMUSG00000049723
ACE 1.0 Y Y 6.1 0.870 ENSMUSG00000020681
COL1A2 1.7 N Y 6.1 0.914 ENSMUSG00000029661
TLR4 0.7 Y Y 5.5 0.786 ENSMUSG00000039005
ITGAX 2.2 Y N 5.4 0.850 ENSMUSG00000030789
VCAN 1.9 N N 4.9 0.910 ENSMUSG00000021614
CLEC7A 1.8 N N 4.7 0.885 ENSMUSG00000079293
N, no; Y, yes.
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proteomics constitute a novel approach that allows early
diagnosis of hepatic ﬁbrosis. This tissue-speciﬁc molecular
signature may lead to the discovery of novel blood-based
biomarkers for early detection of ﬁbrosis. The application
of advanced -omics technology in the search for novel bio-
markers for hepatocellular carcinoma was described
earlier.40 A network biology-based ranking including prior
knowledge from databases and the selected genes and pro-
teins from our tissue-speciﬁc molecular signature was used
to generate a list of candidate blood-based biomarkers.
The set of genes included in the molecular ﬁbrosis signa-
ture consists of markers already known to be related to
existing hepatic ﬁbrosis as well as novel markers. For
example, thrombospontin-1 (THBS1) has been reported to be
part of a gene signature implicated in human chronic liver
disease.41 Our data show that THBS1 is also part of our mo-
lecular ﬁbrosis signature and strongly correlates with colla-
gen1a1 synthesis (R2> 0.95; P< .01). Furthermore, we show
that THBS-1 expression strongly correlates with the histo-
logic grade of ﬁbrosis at week 24 (R2> 0.96; P< .01). On the
other hand, sphingomyelin phosphodiesterase 3, which cat-
alyzes the hydrolysis of sphingomyelin to form ceramide and
phosphocholine, is as far as we know not been reported in
human beings in relation to ﬁbrosis before but also correlates
strongly to the amount of histopathologic ﬁbrosis (R2> 0.88;
P< .01). These data indicate the relevance of the signature for
developing novel biomarker assays and future diagnostics for
early detection of hepatic ﬁbrosis.
Moylan et al42 published a set of 64 genes that differ-
entiate between patients with mild NAFLD (ﬁbrosis stages,
0–1) and severe NAFLD (ﬁbrosis stages, 3–4). These 64
genes are categorized in several biological processes
involved in NAFLD including inﬂammation, metabolism, and
cellular stress responses including oxidative stress and also
ECM formation. The presence of these biological processes
in human NAFLD patients shows similarities with the key
molecular processes as deﬁned in our mouse data set. In
addition, similarities were found on the single gene level as
exempliﬁed by the abundance of insulin-like growth factor
binding protein 7, versican, and ﬁbrilin 1. Differences may
be explained by the fact that our molecular ﬁbrosis signa-
ture was generated based on the correlation between genes
and ECM proteins, thereby emphasizing the ﬁbrotic process,
whereas the data set of 64 genes from Moylan et al42 in-
cludes genes involved in multiple NAFLD- and ﬁbrosis-
related processes. The mouse molecular ﬁbrosis signature
reﬂects speciﬁc aspects of the human ﬁbrosis processes and
therefore can contribute to translational application of the
signature.
In summary, our results show time-resolved regulation
of key molecular processes involved in the development of
NASH and hepatic ﬁbrosis in HFD-fed LDLr-/-.Leiden mice.
We have identiﬁed a molecular ﬁbrosis signature that marks
the active ﬁbrosis process and can be detected before
pathologic ﬁbrosis is present. These data have translational
value and can facilitate further development of candidate
blood-based biomarkers for the early detection of hepatic
ﬁbrosis.
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Supplementary Table 1.List of Newly Synthesized Proteins
as Determined by Dynamic Protein
Proﬁling Ranked by the Number of
Correlating Genes (R2 > 0.95;
P < .05)
Newly synthesized
ECM proteins
Correlating
genes, n
Collagen a-2(I) chain 150
s_Collagen a-2(I) chain 82
s_Collagen a-1(I) chain 70
Collagen a-1(III) chain 66
s_Collagen a-1(VII) chain 49
Hydroxymethylglutaryl-CoA synthase, mitochondrial 43
Laminin subunit g-1 42
Collagen a-1(I) chain 36
s_Keratin, type II cytoskeletal 8 22
s_Collagen a-1(VI) chain 19
3-ketoacyl-CoA thiolase, mitochondrial 12
s_Dermatopontin 11
s_ATP synthase subunit a, mitochondrial 10
Tubulin b-4A chain 9
s_Keratin, type I cytoskeletal 18 7
Tubulin b-4B chain 7
s_Betaine–homocysteine S-methyltransferase 1 5
Collagen a-1(VI) chain 5
Collagen a-2(IV) chain 5
s_Biglycan 4
s_Peptidyl-prolyl cis-trans isomerase A 4
s_60S ribosomal protein L35 3
s_Superoxide dismutase [Cu-Zn] 3
Collagen a-2(VI) chain 3
s_Nidogen-1 2
s_Carbamoyl-phosphate synthase
[ammonia], mitochondrial
1
s_3-ketoacyl-CoA thiolase, mitochondrial 0
s_60-kilodalton heat shock protein, mitochondrial 0
s_Fumarylacetoacetase 0
s_Histone H3.2 0
Collagen a-1(IV) chain 0
Microsomal glutathione S-transferase 1 0
Tubulin b-5 chain 0
NOTE. Proteins marked with an “s” in front of the protein
name were detected in the guanidine-soluble fraction. The
top 8 proteins are included in the molecular signature and
were used for further feature selection.
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Supplementary Table 2.All 232 Genes Included in the Molecular Fibrosis Signature Correlated With the Onset of Fibrosis and Their Ranking Based on the Calculated
Composite Scores
Gene name
Expression
change
(logFC)
Documented
biomarker
for NASH
Documented
biomarker for
hepatic ﬁbrosis
Composite
score ENSMUS-id Reference NASH
Reference hepatic
ﬁbrosis, or other
ﬁbrotic disease
SERPINE1 3.0 Y Y 16.1 ENSMUSG00000037411 Sookoian, Atherosclerosis 2011;218:378 Armendariz-Borunda, J Invest Med
2008;56:944
CCL2 2.0 Y Y 11.2 ENSMUSG00000035385 Leach, 84th European Atherosclerosis
Society (EAS) Congress (May 29 to
June 1, Innsbruck, Austria) 2016,
abstr 083
Page, Am J Gastroenterol
2011;106:abstr 331
COL1A1 2.4 Y Y 10.5 ENSMUSG00000001506 Dattaroy, Am J Physiol Gastrointest Liver
Physiol 2015;308:G298
Decaris, PLoS One 2015;10:e0123311
THBS1 2.1 Y Y 9.3 ENSMUSG00000040152 Smalling, Am J Physiol Gastrointest Liver
Physiol 2013;305:G364
Smalling, Am J Physiol Gastrointest Liver
Physiol 2013;305:G364
CXCL10 2.1 Y Y 9.3 ENSMUSG00000034855 Wada, Digestive Disease Week (May 21–
24, San Diego, CA) 2016, abstr
Sa1670
Andersen, Eur J Clin Microbiol Infect Dis
2011;30:761
CCR2 1.7 Y Y 9.3 ENSMUSG00000049103 Sookoian, Atherosclerosis 2011;218:378 Estrabaud, 65th Annual Meeting of the
American Association for the Study of
Liver Diseases (AASLD) (November
7–11, Boston, MA)
CD14 1.9 Y Y 8.6 ENSMUSG00000051439 Krakora, Conference on Retroviruses
and Opportunistic Infections (CROI)
(February 22–25, Boston, MA) 2016,
abstr 5
Estrabaud, 65th Annual Meeting of the
American Association for the Study of
Liver Diseases (AASLD) (November
7–11, Boston, MA)
IL1RN 2.5 Y N 8.4 ENSMUSG00000026981 Yang, PLoS One 2015;10:e0131664
TNC 1.4 Y N 6.5 ENSMUSG00000028364 Sookoian, Atherosclerosis 2011;218:378 Hisatomi, Intern Med (Tokyo)
2009;48:1501
SMPD3 2.7 N N 6.5 ENSMUSG00000031906 DePianto, Thorax 2015;70:48
PLAU 1.3 N Y 6.3 ENSMUSG00000021822 Andersen, Eur J Clin Microbiol Infect Dis
2011;30:761
COL3A1 1.8 Y Y 6.3 ENSMUSG00000026043 Sookoian, Atherosclerosis 2011;218:378 Decaris, PLoS One 2015;10:e0123311
APOA4 2.6 Y N 6.3 ENSMUSG00000032080 Shores, Digestive Disease Week (May
16–19, Washington, DC) 2015, abstr
Su1036
MMP12 5.2 N Y 6.2 ENSMUSG00000049723 Andersen, Eur J Clin Microbiol Infect Dis
2011;30:761
ACE 1.0 Y Y 6.1 ENSMUSG00000020681 Sookoian, Atherosclerosis 2011;218:378 Granzow, Hepatology 2014;60:334
COL1A2 1.7 N Y 6.1 ENSMUSG00000029661 Decaris, PLoS One 2015;10:e0123311
TLR4 0.7 Y Y 5.5 ENSMUSG00000039005 Sharifnia, Am J Physiol Gastrointest Liver
Physiol 2015;309:G270
Li, J Hepatol 2009;51:750
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Gene name
Expression
change
(logFC)
Documented
biomarker
for NASH
Documented
biomarker for
hepatic ﬁbrosis
Composite
score ENSMUS-id Reference NASH
Reference hepatic
ﬁbrosis, or other
ﬁbrotic disease
ITGAX 2.2 Y N 5.4 ENSMUSG00000030789 Sookoian, Atherosclerosis 2011;218:378
VCAN 1.9 N N 4.9 ENSMUSG00000021614 Estany, 107th International Conference
of the American Thoracic Society
(May 13–18, Denver, CO) 2011, abstr
CLEC7A 1.8 N N 4.7 ENSMUSG00000079293
COL6A3 1.1 Y Y 4.3 ENSMUSG00000048126 Baker, PLoS One 2010;5:e9570 Decaris, PLoS One 2015;10:e0123311
PIK3CG 1.1 N N 4.3 ENSMUSG00000020573 DePianto, Thorax 2015;70:48
VIM 1.1 N Y 4.2 ENSMUSG00000026728 Ando, 65th Annual Meeting of the
American Association for the Study of
Liver Diseases (AASLD) (November
7–11, Boston, MA)
EGR2 3.2 N N 4.2 ENSMUSG00000037868
CD36 0.8 Y N 4.1 ENSMUSG00000002944 Garcia-Monzon, Eur J Clin Invest
2014;44:65
Kang, Nat Med 2015;21:37
TNFAIP3 1.5 Y N 4.1 ENSMUSG00000019850 Sookoian, Atherosclerosis 2011;218:378
TREM2 2.8 N N 3.8 ENSMUSG00000023992
COL4A2 0.8 Y Y 3.5 ENSMUSG00000031503 Abdelmalek, 64th Annual Meeting of the
American Association for the Study of
Liver Diseases (AASLD) (November
1–5, Washington, DC)
Attallah, J Immunoassay Immunochem
2007;28:155
INPP5D 0.8 N Y 3.5 ENSMUSG00000026288 Katsounas, Hepatology 2010;52:abstr
609
CCDC3 1.2 N N 3.5 ENSMUSG00000026676 DePianto, Thorax 2015;70:48
KLF6 1.2 Y N 3.4 ENSMUSG00000000078 Nobili, J Pediatr Gastroenterol Nutr
2014;58:632
DEFB1 2.4 N N 3.4 ENSMUSG00000044748 Han, 107th International Conference of
the American Thoracic Society (May
13–18, Denver, CO) 2011, abstr
CD48 1.2 N Y 3.3 ENSMUSG00000015355 Utsunomiya, World J Gastroenterol
2007;13:383
NR4A3 2.3 N N 3.3 ENSMUSG00000028341
ENPP2 0.7 Y Y 3.2 ENSMUSG00000022425 Arendt, Hepatology 2015;61:1565 Nakagawa, Clin Chim Acta
2011;412:1201
APP 0.4 Y N 3.1 ENSMUSG00000022892 Mendoza, Exp Mol Pathol 2015;98:65 Yang, Am J Respir Crit Care Med
2014;190:1263
TAGLN 1.1 N Y 3.1 ENSMUSG00000032085 Bracht, J Proteome Res 2015;14:2278
STAP1 2.1 N N 3.1 ENSMUSG00000029254
LSP1 1.1 N N 3.1 ENSMUSG00000018819 DePianto, Thorax 2015;70:48
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Reference hepatic
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FBN1 1.0 N Y 3.0 ENSMUSG00000027204 Ippolito, Toxicol Sci 2016;149:67
APOC2 0.7 Y Y 3.0 ENSMUSG00000002992 Baker, PLoS One 2010;5:e9570 Cheung, J Viral Hepat 2009;16:418
CCND1 1.0 N Y 3.0 ENSMUSG00000070348 Sarfraz, BMC Infect Dis (online)
2009;9:125
SYNJ2 2.0 N N 3.0 ENSMUSG00000023805
GPR12 1.9 N N 2.9 ENSMUSG00000041468
CTSS 0.6 N N 2.9 ENSMUSG00000038642 Marmai, Am J Physiol Lung Cell Mol
Physiol 2011;301:L71
MAFF 1.9 N N 2.9 ENSMUSG00000042622
CYGB 0.6 Y N 2.8 ENSMUSG00000020810 Thuy, Am J Pathol 2015;185:1045
COL4A1 0.9 N Y 2.8 ENSMUSG00000031502 Estrabaud, 65th Annual Meeting of the
American Association for the Study of
Liver Diseases (AASLD) (November
7–11, Boston, MA)
F2R 0.6 N N 2.8 ENSMUSG00000048376
PTPRC 0.9 N Y 2.8 ENSMUSG00000026395 Utsunomaiya, World J Gastroenterol
2007;13:383
NUPR1 1.7 N N 2.7 ENSMUSG00000030717
TBXAS1 0.8 N N 2.7 ENSMUSG00000029925
UNC5B 0.8 N Y 2.7 ENSMUSG00000020099 Utsunomiya, World J Gastroenterol
2007;13:383
ENTPD1 0.8 N N 2.7 ENSMUSG00000048120
DUSP5 1.6 N Y 2.6 ENSMUSG00000034765 Ahmad, J Transl Med (online) 2012;10:41
FSTL1 0.8 N N 2.6 ENSMUSG00000022816 Murphy, Am J Pathol 2016;186:600
ANO6 0.8 N N 2.6 ENSMUSG00000064210
FCER1G 0.8 N N 2.6 ENSMUSG00000058715
TGFBI 0.5 Y Y 2.6 ENSMUSG00000035493 Decaris, PLoS One 2015;10:e0123311
COL14A1 0.8 N Y 2.5 ENSMUSG00000022371 Bracht, J Proteome Res 2015;14:2278
MYOF 1.5 N N 2.5 ENSMUSG00000048612
HAUS8 1.4 N N 2.4 ENSMUSG00000035439
TPM1 0.7 N N 2.4 ENSMUSG00000032366 Deng, PLoS One 2013;8:e68352
ARHGAP25 1.4 N Y 2.4 ENSMUSG00000030047 Utsunomiya, World J Gastroenterol
2007;13:383
MX1 1.4 N Y 2.4 ENSMUSG00000000386 PLoS One 2015;10:e0130899
GCNT1 1.4 N N 2.4 ENSMUSG00000038843
IFIT3 1.3 N Y 2.3 ENSMUSG00000074896 Ibrahim, PLoS One 2016;11:e0154512
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Reference hepatic
ﬁbrosis, or other
ﬁbrotic disease
GALNT3 1.3 N N 2.3 ENSMUSG00000026994
MATN2 1.3 N N 2.3 ENSMUSG00000022324
CXCL16 0.7 N N 2.3 ENSMUSG00000018920
SERPINB8 1.3 N N 2.3 ENSMUSG00000026315
TNFRSF11A 1.2 N N 2.2 ENSMUSG00000026321 Boorsma, International Conference of
the American Thoracic Society (May
16–21, San Diego, CA) 2014, abstr
A1252
PLSCR1 1.2 N N 2.2 ENSMUSG00000032369
TLR13 1.2 N N 2.2 ENSMUSG00000033777
ABR 1.1 N N 2.1 ENSMUSG00000017631
CD52 1.1 N Y 2.1 ENSMUSG00000000682 Utsunomiya, World J Gastroenterol
2007;13:383
FGL2 1.1 N Y 2.1 ENSMUSG00000039899 Foerster, J Hepatol 2010;53:608
NFKB2 1.1 N N 2.1 ENSMUSG00000025225
RTN4 0.5 N Y 2.1 ENSMUSG00000020458 Wen, Dis Markers 2015;2015:419124
ITGA4 1.1 N N 2.1 ENSMUSG00000027009
ACOT9 1.0 N N 2.0 ENSMUSG00000025287
FLOT1 0.5 N N 2.0 ENSMUSG00000059714
IFIT2 1.0 N Y 2.0 ENSMUSG00000045932 Ibrahim, PLoS One 2016;11:e0154512
COL16A1 1.0 N N 2.0 ENSMUSG00000040690
ST8SIA4 1.0 N N 2.0 ENSMUSG00000040710
ALDH18A1 1.0 N N 2.0 ENSMUSG00000025007
CSRP1 1.0 N N 2.0 ENSMUSG00000026421
SORL1 1.0 N N 2.0 ENSMUSG00000049313
PPT1 0.5 N N 2.0 ENSMUSG00000028657
BGN 0.5 N Y 2.0 ENSMUSG00000031375 47th Annual Meeting of the European
Association of the Study of the Liver
(EASL) (April 18–22, Barcelona,
Spain) 2012, abstr 105
MLKL 0.9 Y N 1.9 ENSMUSG00000012519 Gautheron, 67th Annual Meeting of the
American Association for the Study of
Liver Diseases (AASLD) (November
11–16, Boston) 20
NID1 0.9 N N 1.9 ENSMUSG00000005397
CDK14 0.9 N N 1.9 ENSMUSG00000028926
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ADCY7 0.9 N N 1.9 ENSMUSG00000031659
HEXB 0.9 N N 1.9 ENSMUSG00000021665
PAK1 0.8 N N 1.8 ENSMUSG00000030774
IGFBP7 0.4 Y N 1.8 ENSMUSG00000036256
PLEKHA1 0.8 N N 1.8 ENSMUSG00000040268
ANXA5 0.8 N N 1.8 ENSMUSG00000027712
TEAD1 0.8 N N 1.8 ENSMUSG00000055320
RGS2 0.8 N N 1.8 ENSMUSG00000026360
CERK 0.8 N N 1.8 ENSMUSG00000035891
SCD2 0.8 N N 1.8 ENSMUSG00000025203
SORBS1 0.7 N N 1.7 ENSMUSG00000025006
CARD10 0.7 N N 1.7 ENSMUSG00000033170 Huang, PLoS One 2014;9:e107055
PLEKHO1 0.7 N N 1.7 ENSMUSG00000015745
SRGN 0.7 N N 1.7 ENSMUSG00000020077
UBA7 0.7 N Y 1.7 ENSMUSG00000032596 Ahmad, J Transl Med (online) 2012;10:41
ACVRL1 0.7 N N 1.7 ENSMUSG00000000530 Chrobak, 19th Annual Congress of the
European Respiratory Sociecy (ERS)
(September 12–16, Vienna, Austria)
2009, abstr
MYO9B 0.7 N N 1.7 ENSMUSG00000004677
PIP4K2A 0.7 N N 1.7 ENSMUSG00000026737
ABCC5 0.7 N N 1.7 ENSMUSG00000022822
RHOC 0.7 N N 1.7 ENSMUSG00000002233
SAT1 0.7 N N 1.7 ENSMUSG00000025283
RHOQ 0.6 N N 1.6 ENSMUSG00000024143
RAB8B 0.6 N N 1.6 ENSMUSG00000036943
GLS 0.6 N N 1.6 ENSMUSG00000026103
HIP1 0.6 N N 1.6 ENSMUSG00000039959
FAR1 0.6 N N 1.6 ENSMUSG00000030759
CC2D2A 0.6 N N 1.6 ENSMUSG00000039765
MYADM 0.6 N N 1.6 ENSMUSG00000068566
ATP8A1 0.6 N N 1.6 ENSMUSG00000037685
SP100 0.6 N N 1.6 ENSMUSG00000026222
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ARMCX3 0.6 Y N 1.6 ENSMUSG00000049047 Higuera, 67th Annual Meeting of the
American Association for the Study of
Liver Diseases (AASLD) (November
11–16, Boston) 2016
ABHD2 0.6 N N 1.6 ENSMUSG00000039202
ITM2C 0.5 N N 1.5 ENSMUSG00000026223 DePianto, Thorax 2015;70:48
PAM 0.4 N N 1.4 ENSMUSG00000026335
MAP4 0.4 N N 1.4 ENSMUSG00000032479
RGS19 1.0 N N 1.0 ENSMUSG00000002458
DENND1C 1.0 N N 1.0 ENSMUSG00000002668
CLCN5 0.5 N N 1.0 ENSMUSG00000004317
PRG4 0.7 N N 1.0 ENSMUSG00000006014
CRIP1 1.1 N N 1.0 ENSMUSG00000006360
APOBEC3 0.9 N N 1.0 ENSMUSG00000009585
FXYD5 1.0 N N 1.0 ENSMUSG00000009687
TMEM86A 0.9 N N 1.0 ENSMUSG00000010307
MCOLN2 1.4 N N 1.0 ENSMUSG00000011008
FCGR1 0.9 N N 1.0 ENSMUSG00000015947
PPFIBP1 0.6 N N 1.0 ENSMUSG00000016487
IKZF1 0.9 N N 1.0 ENSMUSG00000018654
RCN3 0.6 N N 1.0 ENSMUSG00000019539
SLC6A8 1.3 N N 1.0 ENSMUSG00000019558
NUDT4 0.4 N N 1.0 ENSMUSG00000020029
MYO1G 1.1 N N 1.0 ENSMUSG00000020437
GPR137B 1.1 N N 1.0 ENSMUSG00000021306
SLC17A4 1.0 N N 1.0 ENSMUSG00000021336
SEMA4D 1.4 N N 1.0 ENSMUSG00000021451
LRRC14B 0.9 N N 1.0 ENSMUSG00000021579
SAMD4 0.8 N N 1.0 ENSMUSG00000021838
PARVG 1.3 N N 1.0 ENSMUSG00000022439
ST6GAL1 0.7 N N 1.0 ENSMUSG00000022885
MS4A6B 1.2 N N 1.0 ENSMUSG00000024677
MS4A6D 1.5 N N 1.0 ENSMUSG00000024679
MAGED2 0.8 N N 1.0 ENSMUSG00000025268
CPEB1 0.7 N N 1.0 ENSMUSG00000025586
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SGK3 0.5 N N 1.0 ENSMUSG00000025915
COL5A2 1.4 N N 1.0 ENSMUSG00000026042
GPR35 2.1 N N 1.0 ENSMUSG00000026271
FAM129A 0.6 N N 1.0 ENSMUSG00000026483
TAGLN2 0.8 N N 1.0 ENSMUSG00000026547
FRMD4A 0.6 N N 1.0 ENSMUSG00000026657
ZEB2 0.4 N N 1.0 ENSMUSG00000026872
UAP1L1 1.6 N N 1.0 ENSMUSG00000026956
DNAJC10 0.6 N N 1.0 ENSMUSG00000027006
EHD4 0.7 N N 1.0 ENSMUSG00000027293
ARHGEF2 0.9 N N 1.0 ENSMUSG00000028059
CORO2A 1.1 N N 1.0 ENSMUSG00000028337
TTC39A 2.5 N N 1.0 ENSMUSG00000028555
ANXA3 0.7 N N 1.0 ENSMUSG00000029484
OASL2 1.4 N N 1.0 ENSMUSG00000029561
IQGAP1 1.0 N N 1.0 ENSMUSG00000030536
MVP 0.5 N N 1.0 ENSMUSG00000030681
TRIM30A 0.8 N N 1.0 ENSMUSG00000030921
FLNA 1.0 N N 1.0 ENSMUSG00000031328
CTPS2 0.6 N N 1.0 ENSMUSG00000031360
RASA3 0.6 N N 1.0 ENSMUSG00000031453
SLC25A4 0.7 N N 1.0 ENSMUSG00000031633
TPM4 0.5 N N 1.0 ENSMUSG00000031799
TAGAP 1.6 N N 1.0 ENSMUSG00000033450
CHST11 1.7 N N 1.0 ENSMUSG00000034612
FAM124A 0.9 N N 1.0 ENSMUSG00000035184
SSC5D 2.4 N N 1.0 ENSMUSG00000035279
ADAMTS2 1.3 N N 1.0 ENSMUSG00000036545
H2-AA 1.1 N N 1.0 ENSMUSG00000036594
CPZ 1.6 N N 1.0 ENSMUSG00000036596
ABCC12 2.7 N N 1.0 ENSMUSG00000036872
H2-DMA 0.9 N N 1.0 ENSMUSG00000037649
TMEM237 0.8 N N 1.0 ENSMUSG00000038079
RFTN1 0.8 N N 1.0 ENSMUSG00000039316
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PRSS23 0.8 N N 1.0 ENSMUSG00000039405
MYO9A 0.6 N N 1.0 ENSMUSG00000039585
ENC1 0.8 N N 1.0 ENSMUSG00000041773
PTPRE 1.2 N N 1.0 ENSMUSG00000041836
NCAPG2 1.3 N N 1.0 ENSMUSG00000042029
2010003K11RIK 1.7 N N 1.0 ENSMUSG00000042041
SLC35F2 1.7 N N 1.0 ENSMUSG00000042195
GRK3 1.0 N N 1.0 ENSMUSG00000042249
FILIP1L 0.6 N N 1.0 ENSMUSG00000043336
BDH1 0.5 N N 1.0 ENSMUSG00000046598
ARHGAP30 0.7 N N 1.0 ENSMUSG00000048865
THEMIS 1.8 N N 1.0 ENSMUSG00000049109
AMZ1 1.4 N N 1.0 ENSMUSG00000050022
SELENON 0.7 N N 1.0 ENSMUSG00000050989
PLEKHM3 0.8 N N 1.0 ENSMUSG00000051344
WDFY4 0.9 N N 1.0 ENSMUSG00000051506
TCEAL8 0.9 N N 1.0 ENSMUSG00000051579
ZFP608 0.8 N N 1.0 ENSMUSG00000052713
SLFN5 0.7 N N 1.0 ENSMUSG00000054404
CLCA3A1 0.7 N N 1.0 ENSMUSG00000056025
FAM105A 0.8 N N 1.0 ENSMUSG00000056069
PGM3 0.7 N N 1.0 ENSMUSG00000056131
RDH9 1.2 N N 1.0 ENSMUSG00000056148
GLIPR1 1.4 N N 1.0 ENSMUSG00000056888
GM5431 0.8 N N 1.0 ENSMUSG00000058163
TNFRSF19 0.8 N N 1.0 ENSMUSG00000060548
H2-EB1 1.2 N N 1.0 ENSMUSG00000060586
CD200R4 1.4 N N 1.0 ENSMUSG00000062082
CLIP2 0.9 N N 1.0 ENSMUSG00000063146
CD300LB 1.6 N N 1.0 ENSMUSG00000063193
SP140 1.0 N N 1.0 ENSMUSG00000070031
CSF2RB2 1.1 N N 1.0 ENSMUSG00000071714
1810058I24RIK 0.4 N N 1.0 ENSMUSG00000073155
H2-AB1 1.0 N N 1.0 ENSMUSG00000073421
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IFI204 0.8 N N 1.0 ENSMUSG00000073489
WIPF1 0.8 N N 1.0 ENSMUSG00000075284
SLFN1 1.4 N N 1.0 ENSMUSG00000078763
MS4A6C 1.4 N N 1.0 ENSMUSG00000079419
H2-DMB1 1.2 N N 1.0 ENSMUSG00000079547
AI662270 0.8 N N 1.0 ENSMUSG00000087107
ITPRIPL2 0.8 N N 1.0 ENSMUSG00000095115
SOWAHC 0.7 N N 1.0 ENSMUSG00000098188
KCTD12 0.9 N N 1.0 ENSMUSG00000098557
logFC, logarithmic conversion of the fold change (FC).
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